Per Artikel

Riset dan Pengabdian Masyarakat Do Research Sosial Service and Innovation

Id	Authors	Author S Id	Title	Year	Source Title	Volume	Issue	Art No	Page Start	Page End	Cited By	Link	Affiliations	Authors With Affiliations	Abstract	Author Keywords	Index Keywords	Publisher	Issn	Pubmed Id	Document Type	Sjr Best Quartile	Sjr	Sjr Rank
Display # Page 88 of 93 Start Prev 83 84 85 86 87 88 89 90 91 92 Next End
851(1)
No records
596	Dilogo I.H., Rahmatika D., Pawitan J.A., Liem I.K., Kurniawati T., Kispa T., Mujadid F.	56161962800;57474077600;6508348067;55802927800;55213290600;56515348000;57204398571;	Allogeneic umbilical cord-derived mesenchymal stem cells for treating critical-sized bone defects: a translational study	2021	European Journal of Orthopaedic Surgery and Traumatology	31	2		265	273	1	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089486454&doi=10.1007%2fs00590-020-02765-5&partnerID=40&md5=617ce3dfaeed87e7c027f5f3006ebb43	Department of Orthopaedic and Traumatology, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, CMU 2 Building 5th Floor, Jl. Diponegoro 71, Jakarta Pusat, Indonesia; Department Histology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba 6, Jakarta, Indonesia; Stem Cell and Tissue Engineering Research Center, IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jl. Salemba 6, Jakarta, Indonesia	Dilogo, I.H., Department of Orthopaedic and Traumatology, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, CMU 2 Building 5th Floor, Jl. Diponegoro 71, Jakarta Pusat, Indonesia, Stem Cell and Tissue Engineering Research Center, IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rahmatika, D., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, CMU 2 Building 5th Floor, Jl. Diponegoro 71, Jakarta Pusat, Indonesia; Pawitan, J.A., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, CMU 2 Building 5th Floor, Jl. Diponegoro 71, Jakarta Pusat, Indonesia, Department Histology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba 6, Jakarta, Indonesia, Stem Cell and Tissue Engineering Research Center, IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Liem, I.K., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, CMU 2 Building 5th Floor, Jl. Diponegoro 71, Jakarta Pusat, Indonesia, Stem Cell and Tissue Engineering Research Center, IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jl. Salemba 6, Jakarta, Indonesia; Kurniawati, T., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, CMU 2 Building 5th Floor, Jl. Diponegoro 71, Jakarta Pusat, Indonesia, Stem Cell and Tissue Engineering Research Center, IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Kispa, T., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, CMU 2 Building 5th Floor, Jl. Diponegoro 71, Jakarta Pusat, Indonesia; Mujadid, F., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, CMU 2 Building 5th Floor, Jl. Diponegoro 71, Jakarta Pusat, Indonesia	Introduction: The current ‘gold-standard’ treatment of critical-sized bone defects (CSBDs) is autografts; however, they have drawbacks including lack of massive bone source donor site morbidity, incomplete remodeling, and the risk of infection. One potential treatment for treating CSBDs is bone marrow-derived mesenchymal stem cells (BM-MSCs). Previously, there were no studies regarding the use of human umbilical cord-mesenchymal stem cells (hUC-MSCs) for treating BDs. We aim to investigate the use of allogeneic hUC-MSCs for treating CSBDs. Method: We included subjects who were diagnosed with non-union fracture with CSBDs who agreed to undergo hUC-MSCs implantation. All patients were given allogeneic hUC-MSCs. All MSCs were obtained and cultured using the multiple-harvest explant method. Subjects were evaluated functionally using the Lower Extremity Functional Scale (LEFS) and radiologically by volume defect reduction. Result: A total of seven (3 male, 4 female) subjects were recruited for this study. The subjects age ranged from 14 to 62 years. All seven subjects had increased LEFS during the end of the follow-up period, indicating improved functional ability. The follow-up period ranged from 12 to 36 months. One subject had wound dehiscence and infection, and two subjects developed partial union. Conclusion: Umbilical cord mesenchymal stem cells are a potential new treatment for CSBDs. Additional studies with larger samples and control groups are required to further investigate the safety and efficacy of umbilical cord-derived mesenchymal stem cells for treating CSBDs. © 2020, Springer-Verlag France SAS, part of Springer Nature.	Critical-sized bone defect; Mesenchymal stem cells; Umbilical cord	adolescent; adult; allotransplantation; Article; bone defect; clinical article; clinical outcome; critical sized bone defect; female; follow up; fracture nonunion; functional status; human; human cell; Lower Extremity Functional Scale; male; mesenchymal stem cell transplantation; middle aged; priority journal; surgical infection; time to treatment; umbilical cord mesenchymal stem cell; wound dehiscence; young adult; autotransplantation; cell culture; cell differentiation; hematopoietic stem cell transplantation; mesenchymal stem cell; mesenchymal stem cell transplantation; umbilical cord; Adolescent; Adult; Cell Differentiation; Cells, Cultured; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Middle Aged; Transpl	Springer-Verlag Italia s.r.l.	16338065	32804289	Article	Q1	851	5541	View
853(2)
No records
715	Puspita F.M., Yunir E., Agustina P.S., Sauriasari R.	57257264000;36520254800;57217065969;16246507200;	Effect of angiotensin receptor blocker and angiotensin converting enzyme inhibitor on kidney function and blood potassium level in indonesian type 2 diabetes mellitus with hypertension: A three-month cohort study	2021	Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy	14			3841	3849		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114809524&doi=10.2147%2fDMSO.S310091&partnerID=40&md5=4d027eb31fcf71d05393ccf9ca3738b6	Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia	Puspita, F.M., Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; Yunir, E., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Agustina, P.S., Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; Sauriasari, R., Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia	Purpose: National formulary restrictions in Indonesia (2019) require estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 to be able to prescribe telmisartan and valsartan and ACE-I intolerance to be able to prescribe irbesartan and candesartan. These restrictions are based on economic considerations and differ from American Diabetes Association (ADA) (2020) guidelines which allow equal use of angiotensin II receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACE-I) without restriction. Since there is a need to evaluate the different effects of ACE-I and ARB in the Indonesian hypertensive type 2 diabetes mellitus (T2DM) population, we compare their effects on urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and blood potassium level. Patients and Methods: A prospective cohort study at RSUPN Dr. Cipto Mangunkusumo Hospital was conducted in 123 T2DM patients. We followed the study subjects prospectively for three months using a validated questionnaire, health record, and laboratory data. Results: After 3 months of observation, there were no significant changes, except increased BMI values (p = 0.046) in the ACE-I group, and decreased LDL value (p = 0.016) and HDL value (p = 0.004) in the ARB group. Multivariate analysis showed that the consumption of ACE-I or ARB was not associated with a decrease/constant of UACR or increase potassium level, even after adjusting by confounding variables. Interestingly, we found ARB was more likely to increase eGFR, but the significance was lost once the duration of ACE-I/ARB use was entered into the model. In addition, BMI >25 kg/m2 was a significant factor associated with decreased/constant UACR, maleness was significant for increased eGFR, and declining systolic blood pressure for increase in potassium level. Conclusion: ACE-I and ARB have a similar effect on UACR and blood potassium level, but ARB slightly increased eGFR compared to ACE-I within three months of consumption. © 2021 Puspita et al.	Angiotensin II receptor blockers; Angiotensin-converting enzyme inhibitors; Chronic kidney disease; EGFR; Type 2 diabetes mellitus; UACR		Dove Medical Press Ltd	11787007		Article	Q2	853	5525	View
895	Tarigan T.J.E., Dwijayanti A., Setyowati S., Louisa M.	36057746500;55743787900;54893136300;41461551400;	Immunogenicity and efficacy of insulin glargine biosimilar ezelin versus originator insulin glargine in patients with type 2 diabetes	2021	Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy	14			107	116		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099828801&doi=10.2147%2fDMSO.S279385&partnerID=40&md5=4adefbb901a3483328866d6334ab8e3d	Division of Endocrinology and Metabolism, Department of Internal Medicine, Dr. Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Medical Pharmacy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Endocrinology, Department of Internal Medicine, Gatot Soebroto Presidential Hospital, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia	Tarigan, T.J.E., Division of Endocrinology and Metabolism, Department of Internal Medicine, Dr. Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Dwijayanti, A., Department of Medical Pharmacy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Setyowati, S., Division of Endocrinology, Department of Internal Medicine, Gatot Soebroto Presidential Hospital, Jakarta, Indonesia; Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia	Purpose: To compare the immunogenicity and efficacy of insulin glargine biosimilar Ezelin (EZL) versus originator insulin glargine Lantus (LAN) as a reference basal insulin in patients with type 2 diabetes (T2D). Patients and Methods: This was a randomized, multicenter, open-label, 24-week study in insulin-naïve patients with T2D, with HbA1c of >7.0%. We randomly assigned 133 eligible patients to receive either EZL or LAN. Baseline characteristics, including insulin autoantibody (IAA), zinc transporter 8 (ZnT8) antibody, HbA1C, fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2hPPG), AST, ALT, BUN, eGFR, and oral antidiabetic drugs, were obtained before starting insulin treatment. After starting treatment, insulin dose was titrated to achieve FPG target along with oral antidiabetic drugs. Patients were given home glucometer and assisted to record plasma glucose measurement and adverse event (AE). Every month, patients came to the diabetes clinic and performed a regular physical examination and intensifying treatment if needed. Out of the 133 randomized patients, only 122 completed the study and can be examined for their IAA and ZnT8 after 6 months of treatment. The study was registered in clinicaltrials.gov, NCT03352674. Results: There is a similar proportion of patients with changes of IAA from baseline: 1 out of 58 (1.7%) patients receiving EZL versus 1 out of 64 (1.6%) patients receiving LAN (p = 1.000). One patient in the EZL group (1.7%) versus none in the LAN group experienced a change of ZnT8 antibody from baseline. Similar glucose control in EZL versus LAN was determined by the change in HbA1c, FPG, and 2hPPG (−2.0%, −67.46 mg/dL, and −76.51 mg/dL in the EZL group versus −1.7%, −58.11 mg/dL, and −70.03 mg/dL in the LAN group). There were six events of documented hypoglycemia in the EZL group versus five events in the LAN group. No patients experienced diabetic ketoacidosis during the study. Conclusion: Overall, insulin glargine biosimilar EZL and originator insulin glargine LAN have shown a similar immunogenicity profile, as well as efficacy in providing glucose control and safety findings in T2D populations. © 2021 Tarigan et al.	Biosimilar; Hyperglycemia; Insulin autoantibody; Zinc transporter 8 antibody	acarbose; alanine aminotransferase; aspartate aminotransferase; ezelin; glucose; hemoglobin A1c; insulin antibody; insulin glargine; metformin; pioglitazone; protein antibody; sulfonylurea; unclassified drug; urea; zinc transporter 8; zinc transporter 8 antibody; acute gastroenteritis; acute kidney failure; adult; alanine aminotransferase blood level; Article; aspartate aminotransferase blood level; Bell palsy; cardiovascular disease; cerebrovascular accident; cervical spine fracture; controlled study; coughing; dermatitis; diabetic ketoacidosis; diabetic patient; diabetic ulcer; diarrhea; drug dose titration; drug efficacy; drug safety; dyspepsia; dyspnea; estimated glomerular filtration rate; fasting; female; gangrene; gastritis; gastroesophageal reflux; gastrointestinal symptom; glucose	Dove Medical Press Ltd	11787007		Article	Q2	853	5525	View
859(1)
No records
663	Mangunatmadja I., Indra R.M., Widodo D.P., Rafli A.	57195717216;57222298152;57215087823;57210824944;	Risk Factors for Drug Resistance in Epileptic Children with Age of Onset above Five Years: A Case-Control Study	2021	Behavioural Neurology	2021		9092824				https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119934233&doi=10.1155%2f2021%2f9092824&partnerID=40&md5=74ddaa54df43f8e9dd4e310b0bf1246c	Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Child Health, Mohammad Hoesin General Hospital, Universitas Sriwijaya, Medical School, Palembang, Indonesia	Mangunatmadja, I., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Indra, R.M., Department of Child Health, Mohammad Hoesin General Hospital, Universitas Sriwijaya, Medical School, Palembang, Indonesia; Widodo, D.P., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rafli, A., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia	Background. Children with epilepsy with onset above five years encompass distinct epidemiological and clinical characteristics that may have specific risk factors for resistance to antiseizure medications (ASMs). Studies on this age group are limited. Purpose. To identify risk factors for drug resistance in children with epilepsy with the age of onset above five years. Methods. A case-control study was conducted on children with epilepsy with the age of onset above five years visiting the Pediatric Neurology Clinic of Cipto Mangunkusumo and Mohammad Hoesin Hospital between September 2015 and August 2016. Cases consisted of drug-resistant children while control consisted of drug-responsive children according to 2010 ILAE classification. Risk factors studied include onset, number of seizures, illness duration before treatment, cause, seizure type, status epilepticus, initial and evolution of EEG, brain imaging, and initial treatment response. Results. Thirty-two pairs of children were included in the study. After logistic regression analysis, symptomatic etiology and failure to achieve early response to treatment were found to be associated with drug resistance with adjusted OR of 84.71 (95% CI: 5.18-1359.15) and 72.55 (95% CI: 7.08-743.85), respectively. Conclusion. Poor initial response to ASM and symptomatic etiology are independent risk factors for drug resistance in children with epilepsy with the age of onset above five years. © 2021 Irawan Mangunatmadja et al.		anticonvulsive agent; case control study; child; drug resistance; epilepsy; human; onset age; preschool child; risk factor; Age of Onset; Anticonvulsants; Case-Control Studies; Child; Child, Preschool; Drug Resistance; Epilepsy; Humans; Risk Factors	Hindawi Limited	09534180	34804259	Article	Q2	859	5468	View
864(2)
No records
662	Ta J.W.C., Chew D.P., Tsui K.L., Tan D., Duplyakov D., Hammoudeh A., Zhang B., Li Y., Xu K., Ong P.J., Firman D., Gamra H., Almahmeed W., Dalal J., Tam L.-W., Steg G., Nguyen Q.N., Ako J., Al Suwaidi J., Chan M., Sobhy M., Shehab A., Buddhari W., Wang Z., Fong A.Y.Y., Karadag B., Kim B.-K., Baber U., Chin C.T., Han Y.L.	57354736300;7102026332;7101671562;50263435900;6506125408;8088443300;56637270100;55914058500;56510776700;7102312670;54898724100;7004594521;6506558682;7004278395;56585509700;57197860836;39962151600;6701389098;6603728555;23388249600;55345664600;6603838351;57192991797;8875501800;14321654600;56243107600;35189204900;16047315200;57226594604;57211831338;	2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations	2021	European Cardiology Review	16						https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119968735&doi=10.15420%2fecr.2021.35&partnerID=40&md5=0f474aea7166811035b920e727476fae	National Heart Centre, Singapore; Sengkang General Hospital, Singapore; College of Medicine and Public Health, Flinders University, Adelaide, Australia; Pamela Youde Nethersole Eastern Hospital, Hong Kong; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Samara Regional Cardiology Dispensary, Samara, Russian Federation; Cardiology Department, Istishari Hospital, Amman, Jordan; Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore; Tan Tock Seng Hospital, Singapore; Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Cleveland Clinic Abu Dhabi, United Arab Emirates; Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Kwong Wah Hospital, Hong Kong; Department of Cardiology, Hôpital Bichat, Paris, France; Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; National University Heart Centre, Singapore; Faculty of Medicine, Alexandria University, Egypt; College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Sarawak Heart Centre, Kota Samarahan, Malaysia; Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States	Ta, J.W.C., National Heart Centre, Singapore, Sengkang General Hospital, Singapore; Chew, D.P., College of Medicine and Public Health, Flinders University, Adelaide, Australia; Tsui, K.L., Pamela Youde Nethersole Eastern Hospital, Hong Kong; Tan, D., Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Duplyakov, D., Samara Regional Cardiology Dispensary, Samara, Russian Federation; Hammoudeh, A., Cardiology Department, Istishari Hospital, Amman, Jordan; Zhang, B., Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Li, Y., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Xu, K., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Ong, P.J., Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore, Tan Tock Seng Hospital, Singapore; Firman, D., Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Gamra, H., Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Almahmeed, W., Cleveland Clinic Abu Dhabi, United Arab Emirates; Dalal, J., Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Tam, L.-W., Kwong Wah Hospital, Hong Kong; Steg, G., Department of Cardiology, Hôpital Bichat, Paris, France; Nguyen, Q.N., Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Ako, J., Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Al Suwaidi, J., Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; Chan, M., National University Heart Centre, Singapore; Sobhy, M., Faculty of Medicine, Alexandria University, Egypt; Shehab, A., College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; Buddhari, W., King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Wang, Z., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Fong, A.Y.Y., Sarawak Heart Centre, Kota Samarahan, Malaysia; Karadag, B., Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Kim, B.-K., Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; Baber, U., University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Chin, C.T., National Heart Centre, Singapore; Han, Y.L., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China	Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y12inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy. © 2021 Radcliffe Group Ltd. All rights reserved.	Asia; Comorbidity; Consensus; Dual antiplatelet therapy; Myocardial ischaemia; Platelet aggregation inhibitors		Radcliffe Medical Media	17583756		Article	Q2	864	5422	View
765	Tan J.W.C., Chew D.P., Brieger D., Eikelboom J., Montalescot G., Ako J., Kim B.-K., Quek D.K.L., Aitken S.J., Chow C.K., Chour S., Tse H.F., Kaul U., Firdaus I., Kubo T., Liew B.W., Chong T.T., Sin K.Y.K., Yeh H.-I., Buddhari W., Chunhamaneewat N., Hasan F., Fox K.A.A., Nguyen Q.N., Lo S.T.H.	14829599000;7102026332;7004107910;7006303000;7102302494;6701389098;35189204900;57213290935;57225921713;8871779800;57225956090;7006070805;7102340294;55796864700;57226325834;57205155828;36609879000;57223949258;57225966367;57192991797;6505509528;57225971750;57224650893;39962151600;7401542169;	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome	2021	European Cardiology Review	16		e26			3	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109820982&doi=10.15420%2fECR.2020.45&partnerID=40&md5=349f92694e4c018a59343a627d38ced6	National Heart Centre, Singapore, Singapore; Sengkang General Hospital, Singapore, Singapore; College of Medicine and Public Health, Flinders University, Adelaide, Australia; Concord Repatriation General Hospital, University of Sydney, Sydney, Australia; McMaster UniversityON, Canada; Sorbonne University, Paris, France; ACTION Study Group, France; Pitié-Salpêtrière University Hospital (AP-HP), Paris, France; Kitasato University and Hospital, Kanagawa, Japan; Yonsei University College of Medicine, South Korea; Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; University of Sydney, Sydney, Australia; Westmead Applied Research Centre, University of Sydney, Sydney, Australia; Westmead Hospital, Sydney, Australia; Calmette Hospital, Phnom Penh, Cambodia; Queen Mary Hospital, University of Hong Kong, Hong Kong; Batra Hospital and Medical Research Center, New Delhi, India; Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Wakayama Medical University, Wakayama, Japan; Changi General Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore; MacKay Memorial Hospital, MacKay Medical College, Taipei, Taiwan; King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Siriraj Hospital, Mahidol University, Bangkok, Thailand; Heart & Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; University of Edinburgh, Edinburgh, United Kingdom; Hanoi Medical University, Vietnam National Heart Institute, Hanoi, Viet Nam; Liverpool Hospital, Sydney, Australia	Tan, J.W.C., National Heart Centre, Singapore, Singapore, Sengkang General Hospital, Singapore, Singapore; Chew, D.P., College of Medicine and Public Health, Flinders University, Adelaide, Australia; Brieger, D., Concord Repatriation General Hospital, University of Sydney, Sydney, Australia; Eikelboom, J., McMaster UniversityON, Canada; Montalescot, G., Sorbonne University, Paris, France, ACTION Study Group, France, Pitié-Salpêtrière University Hospital (AP-HP), Paris, France; Ako, J., Kitasato University and Hospital, Kanagawa, Japan; Kim, B.-K., Yonsei University College of Medicine, South Korea; Quek, D.K.L., Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; Aitken, S.J., University of Sydney, Sydney, Australia; Chow, C.K., Westmead Applied Research Centre, University of Sydney, Sydney, Australia, Westmead Hospital, Sydney, Australia; Chour, S., Calmette Hospital, Phnom Penh, Cambodia; Tse, H.F., Queen Mary Hospital, University of Hong Kong, Hong Kong; Kaul, U., Batra Hospital and Medical Research Center, New Delhi, India; Firdaus, I., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Kubo, T., Wakayama Medical University, Wakayama, Japan; Liew, B.W., Changi General Hospital, Singapore, Singapore; Chong, T.T., Singapore General Hospital, Singapore, Singapore; Sin, K.Y.K., National Heart Centre, Singapore, Singapore; Yeh, H.-I., MacKay Memorial Hospital, MacKay Medical College, Taipei, Taiwan; Buddhari, W., King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Chunhamaneewat, N., Siriraj Hospital, Mahidol University, Bangkok, Thailand; Hasan, F., Heart & Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Fox, K.A.A., University of Edinburgh, Edinburgh, United Kingdom; Nguyen, Q.N., Hanoi Medical University, Vietnam National Heart Institute, Hanoi, Viet Nam; Lo, S.T.H., Liverpool Hospital, Sydney, Australia	The unique characteristics of patients with chronic coronary syndrome (CCS) in the Asia-Pacific region, heterogeneous approaches because of differences in accesses and resources and low number of patients from the Asia-Pacific region in pivotal studies, mean that international guidelines cannot be routinely applied to these populations. The Asian Pacific Society of Cardiology developed these consensus recommendations to summarise current evidence on the management of CCS and provide recommendations to assist clinicians treat patients from the region. The consensus recommendations were developed by an expert consensus panel who reviewed and appraised the available literature, with focus on data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting recommendations provide guidance on the assessment and management of bleeding and ischaemic risks in Asian CCS patients. Furthermore, the selection of long-term antithrombotic therapy is discussed, including the role of single antiplatelet therapy, dual antiplatelet therapy and dual pathway inhibition therapy. © 2021 Radcliffe Group Ltd. All rights reserved.	Anticoagulant; Antiplatelet; Asia-Pacific; Bleeding; Chronic coronary syndrome; Consensus; Ischaemia	acetylsalicylic acid; anticoagulant agent; clopidogrel; prasugrel; ticagrelor; age; anticoagulant therapy; Article; Asia; bleeding risk score; brain hemorrhage; cardiac patient; consensus; coronary artery disease; dual antiplatelet therapy; gastrointestinal hemorrhage; heart muscle ischemia; high risk patient; human; percutaneous coronary intervention; thrombosis	Radcliffe Medical Media	17583756		Article	Q2	864	5422	View
867(2)
No records
166	Sitohang I.B.S., Sirait S.A.P., Suryanegara J.	56734569200;24482203600;57204535485;	Microneedling in the treatment of atrophic scars: A systematic review of randomised controlled trials	2021	International Wound Journal	18	5		577	585		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100333569&doi=10.1111%2fiwj.13559&partnerID=40&md5=53a0daf4a5ed46e9fefa3f5918f68c9b	Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Sitohang, I.B.S., Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Sirait, S.A.P., Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Suryanegara, J., Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia	To date, treatment of atrophic acne scars remains a therapeutic challenge for dermatologists, yet there is no standard option on the most effective treatment. Microneedling (MN) is a minimally invasive technology that involves repetitive skin puncture using sterile microneedles to disrupt dermal collagen that connects the scar tissue. Recent studies have demonstrated the potency of MN, such as dermaroller and fractionated microneedle radiofrequency, in the treatment of atrophic scars. The objective of this review is to evaluate systematically the current literature on MN for atrophic acne scars. A systematic search of literature was performed from PubMed, Medline, Cochrane Central, and Google Scholar databases for articles published during the last 20 years. Only randomised controlled trials (RCTs) with full-text version of the manuscript available were included in our study. Nine RCTs were included in this review. All treatment modalities demonstrated consistent results that MN was efficacious in treating atrophic acne scars as a monotherapy or in combination with other treatments. Moreover, no serious adverse effects were reported in all studies after MN treatment. MN is a well-tolerated and effective therapeutic modality in treating atrophic acne scars. Further research is required to validate the efficacy of MN with a larger sample size and lengthy follow-up. © 2021 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd.	atrophic acne scar; microneedling	acne vulgaris; atrophy; complication; esthetic surgery; human; needle; pathology; randomized controlled trial (topic); scar; treatment outcome; Acne Vulgaris; Atrophy; Cicatrix; Cosmetic Techniques; Humans; Needles; Randomized Controlled Trials as Topic; Treatment Outcome	John Wiley and Sons Inc	17424801	33538106	Article	Q1	867	5385	View
270	Smith O.J., Wicaksana A., Davidson D., Spratt D., Mosahebi A.	54881691700;57211445559;55553306500;7004394482;55985666400;	An evaluation of the bacteriostatic effect of platelet-rich plasma	2021	International Wound Journal	18	4		448	456	2	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100215304&doi=10.1111%2fiwj.13545&partnerID=40&md5=1f9c16fc126205b4735c175e68af0b2e	Department of Plastic Surgery, Royal Free Hospital, London, United Kingdom; Division of Surgery and Interventional Science, University College London, London, United Kingdom; Division of Plastic Surgery, Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; Microbial Diseases, Eastman Dental Institute, Faculty of Medical Sciences, University College London, London, United Kingdom	Smith, O.J., Department of Plastic Surgery, Royal Free Hospital, London, United Kingdom, Division of Surgery and Interventional Science, University College London, London, United Kingdom; Wicaksana, A., Division of Surgery and Interventional Science, University College London, London, United Kingdom, Division of Plastic Surgery, Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; Davidson, D., Microbial Diseases, Eastman Dental Institute, Faculty of Medical Sciences, University College London, London, United Kingdom; Spratt, D., Microbial Diseases, Eastman Dental Institute, Faculty of Medical Sciences, University College London, London, United Kingdom; Mosahebi, A., Department of Plastic Surgery, Royal Free Hospital, London, United Kingdom, Division of Surgery and Interventional Science, University College London, London, United Kingdom	Chronic wounds are a considerable health burden with high morbidity and poor rates of healing. Colonisation of chronic wounds by bacteria can be a significant factor in their poor healing rate. These bacteria can develop antibiotic resistance over time and can lead to wound infections, systemic illness, and occasionally amputation. When a large number of micro-organisms colonise wounds, they can lead to biofilm formation, which are self-perpetuating colonies of bacteria closed within an extracellular matrix, which are poorly penetrated by antibiotics. Platelet-rich plasma (PRP) is an autologous blood product rich in growth factors and cytokines that are involved in an inflammatory response. PRP can be injected or applied to a wound as a topical gel, and there is some interest regarding its antimicrobial properties and whether this can improve wound healing. This study aimed to evaluate the in vitro bacteriostatic effect of PRP. PRP was collected from healthy volunteers and processed into two preparations: activated PRP—activated with calcium chloride and ethanol; inactivated PRP. The activity of each preparation against Staphylococcus aureus and Staphylococcus epidermis was evaluated against a control by three experiments: bacterial kill assay to assess planktonic bacterial growth; plate colony assay to assess bacterial colony growth; and colony biofilm assay to assess biofilm growth. Compared with control, both preparations of PRP significantly inhibited growth of planktonic S aureus and S epidermis. Activated PRP reduced planktonic bacterial concentration more than inactivated PRP in both bacteria. Both PRP preparations significantly reduced bacterial colony counts for both bacteria when compared with control; however, there was no difference between the two. There was no difference found between biofilm growth in either PRP against control or against the other preparation. This study demonstrates that PRP does have an inhibitory effect on the growth of common wound pathogens. Activation may be an important factor in increasing the antimicrobial effect of PRP. However, we did not find evidence of an effect against more complex bacterial colonies. © 2021 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd.	antimicrobial therapy; chronic wounds; platelet-rich plasma	alcohol; calcium chloride; antiinfective agent; Article; bacterial count; bacterial growth; bacterial strain; bacteriostatic activity; bacterium colony; biofilm; controlled study; extracellular matrix; in vitro study; nonhuman; Staphylococcus aureus; Staphylococcus epidermidis; thrombocyte activation; thrombocyte rich plasma; human; Staphylococcus infection; wound healing; wound infection; Anti-Bacterial Agents; Humans; Platelet-Rich Plasma; Staphylococcal Infections; Wound Healing; Wound Infection	John Wiley and Sons Inc	17424801	33476481	Article	Q1	867	5385	View
869(1)
No records
810	Suwantika A.A., Zakiyah N., Abdulah R., Sitohang V., Tandy G., Anartati A., Hidayatullah T., Herliana P., Hadinegoro S.R.	55757798100;56073623400;9244834900;57201802658;57208105012;35602938500;35117792500;57203394399;57226218772;	Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia	2021	Journal of Environmental and Public Health	2021		7494965				https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105700019&doi=10.1155%2f2021%2f7494965&partnerID=40&md5=bbd858611fb710b7cc2cabf814a8c66b	Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, 45363, Indonesia; Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, 45363, Indonesia; Directorate of Health Surveillance and Quarantine, Directorate General of Disease Prevention and Control, Ministry of Health, Jakarta, 12750, Indonesia; Clinton Health Access Initiative, Jakarta, 10450, Indonesia; Department of Child Health, Faculty of Medicine, Universitas Indonesia, Jakarta, 10440, Indonesia	Suwantika, A.A., Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, 45363, Indonesia, Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, 45363, Indonesia; Zakiyah, N., Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, 45363, Indonesia, Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, 45363, Indonesia; Abdulah, R., Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, 45363, Indonesia, Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, 45363, Indonesia; Sitohang, V., Directorate of Health Surveillance and Quarantine, Directorate General of Disease Prevention and Control, Ministry of Health, Jakarta, 12750, Indonesia; Tandy, G., Directorate of Health Surveillance and Quarantine, Directorate General of Disease Prevention and Control, Ministry of Health, Jakarta, 12750, Indonesia; Anartati, A., Clinton Health Access Initiative, Jakarta, 10450, Indonesia; Hidayatullah, T., Clinton Health Access Initiative, Jakarta, 10450, Indonesia; Herliana, P., Clinton Health Access Initiative, Jakarta, 10450, Indonesia; Hadinegoro, S.R., Department of Child Health, Faculty of Medicine, Universitas Indonesia, Jakarta, 10440, Indonesia	As a country with the high number of deaths due to pneumococcal disease, Indonesia has not yet included pneumococcal vaccination into the routine program. This study aimed to analyse the cost-effectiveness and the budget impact of pneumococcal vaccination in Indonesia by developing an age-structured cohort model. In a comparison with no vaccination, the use of two vaccines (PCV10 and PCV13) within two pricing scenarios (UNICEF and government contract price) was taken into account. To estimate the cost-effectiveness value, a 5-year time horizon was applied by extrapolating the outcome of the individual in the modelled cohort until 5 years of age with a 1-month analytical cycle. To estimate the affordability value, a 6-year period (2019-2024) was applied by considering the government's strategic plan on pneumococcal vaccination. In a comparison with no vaccination, the results showed that vaccination would reduce pneumococcal disease by 1,702,548 and 2,268,411 cases when using PCV10 and PCV13, respectively. Vaccination could potentially reduce the highest treatment cost from the payer perspective at $53.6 million and $71.4 million for PCV10 and PCV13, respectively. Applying the UNICEF price, the incremental cost-effectiveness ratio (ICER) from the healthcare perspective would be $218 and $162 per QALY-gained for PCV10 and PCV13, respectively. Applying the government contract price, the ICER would be $987 and $747 per QALY-gained for PCV10 and PCV13, respectively. The result confirmed that PCV13 was more cost-effective than PCV10 with both prices. In particular, introduction cost per child was estimated to be $0.91 and vaccination cost of PCV13 per child (3 doses) was estimated to be $16.61 and $59.54 with UNICEF and government contract prices, respectively. Implementation of nationwide vaccination would require approximately $73.3-$75.0 million (13-14% of routine immunization budget) and $257.4-$263.5 million (45-50% of routine immunization budget) with UNICEF and government contract prices, respectively. Sensitivity analysis showed that vaccine efficacy, mortality rate, and vaccine price were the most influential parameters affecting the ICER. In conclusion, pneumococcal vaccination would be a highly cost-effective intervention to be implemented in Indonesia. Yet, applying PCV13 with UNICEF price would give the best cost-effectiveness and affordability values on the routine immunization budget. © 2021 Auliya A. Suwantika et al.		pcv 10; Pneumococcus vaccine; Pneumococcus vaccine; Article; budget; budget impact analysis; case control study; case fatality rate; child; cohort analysis; comparative effectiveness; contract; controlled study; cost effectiveness analysis; drug cost; drug efficacy; economic evaluation; government; health care cost; human; incidence; incremental cost effectiveness ratio; Indonesia; infection prevention; mortality rate; outcome assessment; pneumococcal infection; price; quality adjusted life year; sensitivity analysis; strategic planning; Streptococcus pneumonia; United Nations Children's Fund; vaccination; cost benefit analysis; economics; Budgets; Child; Cost-Benefit Analysis; Humans; Indonesia; Pneumococcal Vaccines; Vaccination	Hindawi Limited	16879805	33995536	Article	Q2	869	5372	View
882(1)
No records
110	Abdullah M., Sukartini N., Nursyirwan S.A., Pribadi R.R., Maulahela H., Utari A.P., Muzellina V.N., Wiraatmadja A., Renaldi K.	7103393434;6505680329;57249143800;57194732282;57189612709;57113585900;57223968527;57249709700;57190963547;	Gut Microbiota Profiles in Early-and Late-Onset Colorectal Cancer: A Potential Diagnostic Biomarker in the Future	2021	Digestion	102	6		823	832	1	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114428104&doi=10.1159%2f000516689&partnerID=40&md5=b8c0c7b633dbb180aa40d5f20e5481d7	Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Human Cancer Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Clinical Pathology, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia	Abdullah, M., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia, Human Cancer Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Sukartini, N., Department of Clinical Pathology, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Nursyirwan, S.A., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Pribadi, R.R., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Maulahela, H., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Utari, A.P., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Muzellina, V.N., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Wiraatmadja, A., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Renaldi, K., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia	Background: Researchers believe the role of gut microbiota dysbiosis in the raised incidence of early-onset colorectal cancer (EOCRC). The development of EOCRC may be associated with microbiota dysbiosis either dependently or independently (combined with other risk factors). Summary: Recently, the rising of incidence and mortality of EOCRC have been noted. Some researchers are looking for risk factors influencing this fact. They hypothesize that it may be because of microbiota dysbiosis. Microbiota dysbiosis has been known to promote cancer development through immunity dysregulation and chronic inflammation. Microbiomes profile in late-onset colorectal cancer (LOCRC) among older patients has been documented, but there is still lack of data about microbial profiles among younger colorectal cancer (CRC) patients. This review tries to explain microbial profiles differences between EOCRC and LOCRC as a potential diagnostic biomarker in the future, and whether microbiota can have a role in EOCRC genesis. Key Messages: Microbiota does vary with age, and EOCRC may be associated with colonization of some specific bacteria. Further studies about gut microbiota profiles in EOCRC and LOCRC may provide a new insight on diagnostic biomarker of CRC. © 2021 S. Karger AG, Basel. Copyright: All rights reserved.	Colorectal cancer; Diagnostic biomarker; Early-onset colorectal cancer; Gut microbiota; Microbiota dysbiosis	biological marker; colorectal tumor; dysbiosis; human; incidence; intestine flora; Biomarkers; Colorectal Neoplasms; Dysbiosis; Gastrointestinal Microbiome; Humans; Incidence	S. Karger AG	00122823	34433172	Review	Q2	882	5279	View

Publikasi Scopus 926 artikel (Per 14 Maret 2022)